DiaMedica Therapeutics Inc (DMAC)vsJohnson & Johnson (JNJ)
DMAC
DiaMedica Therapeutics Inc
$8.33
-5.23%
HEALTHCARE · Cap: $474.29M
JNJ
Johnson & Johnson
$282.84
-1.12%
HEALTHCARE · Cap: $682.52B
Smart Verdict
WallStSmart Research — data-driven comparison
JNJ leads profitability with a 16.2% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 54/100 (C-).
DMAC
Avoid20
out of 100
Grade: F
JNJ
Buy54
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 26.6%
Generating 6.4B in free cash flow
Areas to Watch
Trading at 15.7x book value
0.0% revenue growth
0.0% earnings growth
Distress zone — elevated risk
Trading at 8.4x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : DMAC
The strongest argument for DMAC centers on Debt/Equity.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 26.6%.
Bear Case : DMAC
The primary concerns for DMAC are Price/Book, Revenue Growth, EPS Growth.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 43.0x leaves little room for execution misses.
Key Dynamics to Monitor
DMAC profiles as a value stock while JNJ is a mature play — different risk/reward profiles.
DMAC carries more volatility with a beta of 0.94 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (54/100 vs 20/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DiaMedica Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis, Minnesota.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?